Browsing Tag
CAR T-cell therapy
6 posts
Why AACR 2026 data on FT839 matters for hematologic cancer and autoimmune markets
Find out how Fate Therapeutics, Inc.’s FT839 could reshape CAR T economics and expand into autoimmune disease markets. Read the full analysis.
Gilead Sciences to double down on CAR T with $7.8bn Arcellx acquisition
Find out how Gilead Sciences’ $7.8 billion Arcellx acquisition reshapes the future of anito-cel and the competitive landscape in multiple myeloma.
Fate Therapeutics reports encouraging Phase 1 progress for FT819 as off-the-shelf CAR T therapy targets durable lupus remission
Find out how Fate Therapeutics is advancing FT819 as an off-the-shelf CAR T therapy for lupus and why its Phase 1 data could reshape autoimmune treatment.
Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings
Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update.
Pfizer’s ADCETRIS combination regimen secures FDA approval for relapsed large B-cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s supplemental Biologics License Application (sBLA) for ADCETRIS…
Lyell Immunopharma to acquire ImmPACT—are CAR T-cell therapies the future of oncology?
Lyell Immunopharma is making waves with its strategic acquisition of ImmPACT Bio, a move aimed at bolstering its…